Key Points Iovance Biotherapeutics' cancer therapy, Amtagvi, is experiencing decent sales growth. However, the biotech faces some challenges that will make it difficult to turn a profit. Though there could be some catalysts on the way, Iovance's prospects seem too risky. 10 stocks we like better than Iovance Biotherapeutics › Last year, Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech, made a major breakthrough. The company earned approval for Amtagvi, which became the first medicine o ...